Analysts Offer Insights on Healthcare Companies: Kite Pharma Inc (NASDAQ: KITE) and Shire (NASDAQ: SHPG)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kite Pharma Inc (NASDAQ: KITE) and Shire (NASDAQ: SHPG) with bullish sentiments.

Kite Pharma Inc (NASDAQ: KITE)

Jefferies analyst Biren Amin reiterated a Buy rating on Kite Pharma Inc (NASDAQ: KITE) yesterday and set a price target of $101. The company’s shares closed yesterday at $81.15.

According to TipRanks.com, Amin is a 4-star analyst with an average return of 2.9% and a 48.4% success rate. Amin covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Lion Biotechnologies Inc, and Bellicum Pharmaceuticals.

Currently, the analyst consensus on Kite Pharma Inc is Moderate Buy and the average price target is $80.40, representing a -0.9% downside.

In a report released yesterday, Canaccord Genuity also reiterated a Buy rating on the stock with a $90 price target.
Shire (NASDAQ: SHPG)

Jefferies analyst David Steinberg reiterated a Buy rating on Shire (NASDAQ: SHPG) yesterday and set a price target of $239. The company’s shares closed yesterday at $171.86.

According to TipRanks.com, Steinberg is a 3-star analyst with an average return of 2.1% and a 46.9% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.

Currently, the analyst consensus on Shire is Strong Buy and the average price target is $250, representing a 45.5% upside.

In a report issued on April 10, Stifel Nicolaus also maintained a Buy rating on the stock with a $250 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.